The Phase 3 trial investigating Dapagliflozin (NCT06820567) for its effects on inflammatory markers, erythropoiesis, and iron metabolism in patients with Type 2 Diabetes and Chronic Kidney Disease has completed its primary phase on 2026-03-01. This study enrolled 210 participants.
Background
The trial, titled "Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD," is designed to compare the effect of dapagliflozin versus placebo on erythropoiesis, iron metabolism, and inflammatory markers in patients with Chronic Kidney Disease and Type 2 Diabetes.
Trial design
The study (NCT06820567) is a Phase 3 trial with an estimated enrollment of 210 participants. It investigates dapagliflozin and placebo in patients diagnosed with Chronic Kidney Diseases and Type 2 Diabetes. The trial aims to compare the effects of these interventions on erythropoiesis, iron metabolism, and inflammatory markers.
What this means
The primary completion of this Phase 3 trial for dapagliflozin indicates a significant milestone in its investigation for patients with Type 2 Diabetes and Chronic Kidney Disease. While specific outcome data are not yet available, the completion of this phase suggests that the study is progressing as planned. Future data releases will provide insights into dapagliflozin's potential effects on inflammatory markers, erythropoiesis, and iron metabolism in this patient population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06820567 was posted on 2026-03-01 on clinicaltrials.gov.